413 Thalamic Neuromodulation for Pediatric Drug-Resistant Epilepsy: A Case Series Evaluating Deep Brain Stimulation and Responsive Neurostimulation

View at publisher Summarise with VIRAT
Authors: Dominic A. Nistal, Adriel Barrios-Anderson, Scott H. Boop, Benjamin D. Edmonds, Matthew J. Recker, Jeffrey G. Ojemann, Robert T. Buckley, Jason Scott Hauptman, Hannah E. Goldstein
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Non-lesional drug-resistant epilepsy (DRE) in children is difficult to manage, with limited treatment options. Recent advances in deep brain stimulation (DBS) and responsive neurostimulation (RNS) have shown seizure reduction in adults, particularly with thalamic targets for generalized multifocal epilepsy. However, their safety and efficacy remain understudied in the pediatric population. This is the largest pediatric study to date evaluating the safety of thalamic neuromodulation using RNS and DBS in children. METHODS: A retrospective chart review identified pediatric patients with non-lesional DRE who underwent intracranial neuromodulatory treatment (RNS or DBS) targeting thalamic nuclei at Seattle Children’s Hospital from 2020 to present. Surgical and functional outcomes were assessed. RESULTS: Twenty-six patients underwent thalamic neuromodulation with DBS (n = 12) or RNS (n = 14), with a mean age of 14.5 years (range 6–20). Twenty-one had Lennox-Gastaut Syndrome (80.7%) with generalized multifocal epilepsy. Seven patients (33.3%) had prior resective epilepsy surgery, and 21 (80.7%) had prior vagus nerve stimulation (VNS). The centromedian nucleus (CM) was the target in 24 patients; one patient had anterior nucleus of the thalamus (ANT), and one had pulvinar. No serious adverse events occurred. Median hospital stay was 2 days (range 1–13), with median follow-up of 22.0 months (range 1.8–54.1). One patient required explantation for wound infection. Two patients discontinued therapy—one due to ineffectiveness and one due to behavioral changes. Nineteen patients experienced seizure improvement, with a mean reduction of 40.1%. CONCLUSIONS: Thalamic neuromodulation with RNS or DBS is safe and well tolerated in pediatric patients. This surgical approach offers a promising treatment option for severe, multifocal pediatric epilepsy. Future prospective studies are needed to better understand long-term outcomes and guide device selection and target nucleus choice.

Fields of Study & Subjects

Epilepsy research and treatment Deep Brain Stimulation and Movement Disorders Vagus Nerve Stimulation Research

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
117–117
Publication date
26 March 2026
Language
EN